Glooko and MyLife Diabetes Care announced today that they agreed to expand their partnership centered around diabetes management products.
Under their agreement, Glooko serves as MyLife Diabetes Care’s primary data management platform for MyLife products.
Glooko offers diabetes management platforms such as EndoTool, a leading software platform that offers capabilities for inpatient insulin dosing and glycemic management. The FDA-cleared platform delivers assistance in optimizing insulin dosing, using a patient-specific algorithm in real-time. It helps reduce the risk of hypoglycemia and helps hospitals meet CMS quality measures while streamlining clinical workflows.
MyLife, the former diabetes care unit of Ypsomed, offers the Ypsomed MyLife Loop tube pump system, which includes the MyLife YpsoPump and automated insulin delivery solution CamAPS FX, with its own patch pump program.
Under their expanded agreement, MyLife plans to further strengthen its digital ecosystem with Glooko’s management platform. It aims to make access to its data more readily available.
This latest step builds on a well-established collaboration between the two companies, ensuring continuity for healthcare providers and patients.
Commentary from Glooko and MyLife officials
Mike Alvarez, Glooko CEO, said:
“Diabetes care is increasingly connected, and data management is one of the most important layers in helping people with diabetes and care teams make sense of information across devices and therapies. We’re proud that mylife Diabetes Care has selected Glooko as its preferred data management partner. We’re excited to build on our strong partnership and support a smoother, more connected experience for mylife users and their healthcare teams.”
Sébastien Delarive, MyLife CEO, said:
“As a leader in innovative AID solutions, we are committed to turning complex therapy into seamless, empowering experiences for people living with diabetes and the healthcare professionals who support them. As AID and connected therapy models continue to grow, accessible and shareable diabetes data is increasingly important for everyday care.”
